

Treatment-Experienced

Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1)

Source: Poordad F, et al. Hepatology. 2017;66:389-97.

Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Study Features

MAGELLAN-1 (Part 1) Trial

- **Design:** Randomized, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the glecaprevir plus pibrentasvir, with or without ribavirin, for 12 weeks in patients with GT 1 chronic HCV (without cirrhosis) who previously experienced virologic failure with direct-acting antiviral (DAA) therapy.
- **Setting:** Multiple centers in United States
- **Key Eligibility Criteria**
 - Chronic HCV GT 1
 - Age 18-70
 - Prior treatment failure with DAA regimen
 - Patients with cirrhosis excluded
 - Patients with HIV or HBV coinfection excluded
- **Primary End-Point:** SVR12


Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Treatment Regimens

Week

0

12

24



Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Baseline Characteristics

Characteristics	GLE 200 mg + PIB 80 mg n = 6	GLE 300 + PIB 120 mg + RBV 800 mg n = 22	GLE 200 mg + PIB 120 mg n = 22
Age, median years (range)	59 (39-61)	56 (39-64)	59 (46-70)
Male sex, n (%)	3 (50)	20 (91)	18 (82)
Black race, n (%)	2 (33)	5 (23)	10 (45)
BMI, median kg/m ² (range)	27 (25-37)	28 (22-34)	28 (19-37)
IL28B non-CC genotype, n (%)	4 (67)	16 (73)	19 (86)
HCV RNA level, median log ₁₀ IU/ml (range)	6.1 (5.6-6.7)	6.7 (5.0-7.3)	6.6 (5.5-7.2)
Fibrosis stage, n (%)			
F0-F1	4 (67)	17 (77)	11 (50)
F2	1 (17)	0	6 (27)
F3	1 (17)	5 (23)	5 (23)
HCV subtype 1a, n/N (%)	4 (67)	20 (91)	19 (82)

GLE-PIB = glecaprevir-pibrentasvir; RBV = ribavirin; BMI = body mass index


Source: Poordad F, et al. *Hepatology*. 2017;66:389-97.

Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Baseline Characteristics

Characteristics	GLE 200 + PIB 80 mg n = 6	GLE 300 + PIB 120 mg + RBV 800 mg n = 22	GLE 200 + PIB 120 mg n = 22
Prior DAA class, n (%)			
NS5A-experienced/PI-naïve	0	4 (18)	4 (18)
NS5A-naïve/PI-experienced	3 (50)	11 (50)	11 (50)
NS5A-experienced/PI-experienced	3 (50)	7 (32)	7 (32)
Baseline polymorphisms, n (%)			
Any (NS3 or NS5A)	5 (83)	18 (82)	17 (77)
NS3 only	2 (33)	7 (32)	5 (23)
NS5A only	3 (50)	5 (23)	3 (14)
Both NS3 and NS5A	0	6 (27)	9 (41)

GLE-PIB = glecaprevir-pibrentasvir

Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Study Design



Source: Poordad F, et al. Hepatology. 2017;66:389-97.

Glecaprevir-Pibrentasvir in HCV GT 1 & Prior DAA Treatment MAGELLAN-1 (Part 1): Conclusions

Conclusions: “The combination of glecaprevir and pibrentasvir was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; ribavirin coadministration did not improve efficacy.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.